Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib + venetoclax followed by MRD-guided rituximab for relapsed/refractory hairy cell leukemia
2026-527434-31-00Phase 2Withdrawn
- Sponsor
- Azienda Ospedaliera di Perugia
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib, venetoclax and rituximab in hairy cell leukemia (HCL), sponsored by Azienda Ospedaliera di Perugia. Primary endpoint: Complete remission rate after 4 cycles of vemurafenib + venetoclax. Planned start Nov 2026; status: withdrawn.
02
Drugs
vemurafenibvenetoclaxrituximab
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on 2026-527434-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527434-31-00.